Disparities in OncotypeDx Testing and Subsequent Chemotherapy Receipt by Geography and Socioeconomic Status.

Sarah C Van Alsten Matthew R Dunn Alina M Hamilton Joannie M Ivory Xiaohua Gao Erin L Kirk Joseph S Nsonwu-Farley Lisa Anne Carey Yara G Abdou Katherine E Reeder-Hayes Mya L Roberson Stephanie B Wheeler Marc A Emerson Terry Hyslop Melissa A Troester

Published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (2024)

Variable adoption of OncotypeDx by socioeconomics and across geographic settings may contribute to excess chemotherapy among HR+/HER2- patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
locally advanced
prognostic factors
healthcare
radiation therapy